
Keywords: prostatic neoplasms; testosterone; hypogonadism; prostate-specific antigen; risk factors; AR; androgen receptor; BMI; body mass index; CV; coefficient of variation; MMD; median of maximum declines in 24-month screening window; MMDRM; ratio of maximum decl